Cargando…

A novel smartphone scleral‐image based tool for assessing jaundice in decompensated cirrhosis patients

BACKGROUND AND AIM: Serum bilirubin is an established marker of liver disease. Reliable tools for non‐invasive assessment of jaundice in cirrhosis patients, at risk of clinical decompensation, are highly desirable. While smartphone‐based imaging has been described in neonatal jaundice, it has not be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kazankov, Konstantin, Nixon‐Hill, Miranda, Kumar, Rahul, Amin, Ahmed, Alabsawy, Eman, Chikhlia, Anmol, Leung, Terence S., Mookerjee, Rajeshwar P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles ‐ Hepatology (Clinical)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107452/ https://www.ncbi.nlm.nih.gov/pubmed/36574965 http://dx.doi.org/10.1111/jgh.16093

Ejemplares similares

Negative impact of the pandemic on hospital admissions, morbidity and early mortality for acute cirrhosis decompensation
por: Gananandan, Kohilan, et al.
Publicado: (2023)

Assessment of bilirubin levels in patients with cirrhosis via forehead, sclera and lower eyelid smartphone images
por: Nixon-Hill, Miranda, et al.
Publicado: (2023)

Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis
por: Rivas, Gloriany, et al.
Publicado: (2021)

Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)
por: Weiss, Emmanuel, et al.
Publicado: (2023)

PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis
por: Dunn, Winston, et al.
Publicado: (2019)

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation
por: Monteiro, Sofia, et al.
Publicado: (2021)

Predicting 1-year mortality among patients with decompensated cirrhosis: results of a multicentre evaluation of the Bristol Prognostic Score
por: Bowers, Sarah Pauline, et al.
Publicado: (2022)

Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis
por: Khamri, Wafa, et al.
Publicado: (2022)

A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
por: Xie, Yanan, et al.
Publicado: (2022)

Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case–control study
por: Xu, Xiaomei, et al.
Publicado: (2021)

Effect of COVID-19 on presentations of decompensated liver disease in Scotland
por: Manship, Thomas, et al.
Publicado: (2022)

Smartphone screening for neonatal jaundice via ambient-subtracted sclera chromaticity
por: Outlaw, Felix, et al.
Publicado: (2020)

Hepatic decompensation in the absence of obvious precipitants: the potential role of cytomegalovirus infection/reactivation
por: Rosi, Silvia, et al.
Publicado: (2015)

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial
por: Vilar Gomez, Eduardo, et al.
Publicado: (2011)

A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study
por: Mao, Hao-dan, et al.
Publicado: (2023)

Changing trends of hospitalisation of liver cirrhosis in Beijing, China
por: Bao, Xiao-Yuan, et al.
Publicado: (2015)

Fat mass: a novel digital biomarker for remote monitoring that may indicate risk for malnutrition and new complications in decompensated cirrhosis
por: Gananandan, K., et al.
Publicado: (2023)

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis
por: Pose, Elisa, et al.
Publicado: (2021)

High plasma soluble thrombomodulin levels indicated poor prognosis of decompensated liver cirrhosis: a prospective cohort study
por: Wei, Xinhuan, et al.
Publicado: (2022)

Opioid and benzodiazepine prescription among patients with cirrhosis compared to other forms of chronic disease
por: Konerman, Monica A, et al.
Publicado: (2019)

Aflatoxin B(1) exposure and liver cirrhosis in Guatemala: a case–control study
por: Alvarez, Christian S, et al.
Publicado: (2020)

Value and risk of percutaneous liver biopsy in patients with cirrhosis and clinical suspicion of autoimmune hepatitis
por: Sripongpun, Pimsiri, et al.
Publicado: (2021)

Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study
por: Johnson, Amy L, et al.
Publicado: (2021)

Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies
por: Middleton, Paul, et al.
Publicado: (2021)

A Case of Obstructive Jaundice
por: Veloso, Nuno, et al.
Publicado: (2015)

Factors associated with renal dysfunction in hepatitis C-related cirrhosis and its correlation with Child-Pugh score
por: Bhatti, Hamza Waqar, et al.
Publicado: (2019)

Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis
por: Khan, Adnan Aman, et al.
Publicado: (2020)

Development of a national Department of Veterans Affairs mortality risk prediction model among patients with cirrhosis
por: Koola, Jejo David, et al.
Publicado: (2019)

Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: a retrospective observational cohort study
por: Lee, Nerissa Hoi Ching, et al.
Publicado: (2023)

Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study
por: Buch, Stephan, et al.
Publicado: (2023)

Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function
por: Blasco-Algora, Sara, et al.
Publicado: (2016)

Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
por: Elsayed, Amr, et al.
Publicado: (2020)

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation
por: Yuan, Lunzhi, et al.
Publicado: (2019)

Lower survival and higher rates of cirrhosis in patients with ROUX-EN-Y gastric bypass hospitalised with alcohol-associated hepatitis
por: Anugwom, Chimaobi, et al.
Publicado: (2023)

The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa
por: Lemoine, Maud, et al.
Publicado: (2016)

Study protocol for a randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE trial)
por: Tripathi, Dhiraj, et al.
Publicado: (2019)

Deep-Learning-Based Smartphone Application for Self-Diagnosis of Scleral Jaundice in Patients with Hepatobiliary and Pancreatic Diseases
por: Park, Joon Hyeon, et al.
Publicado: (2021)

Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)
por: de Wit, K, et al.
Publicado: (2020)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_850qtfvhh4jji5u2l6ei26u7fj